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Growth factor receptor signaling via receptor tyrosine kinases (RTKs) is one of the basic cellular
communication principals found in all metazoans. Extracellular signals are transferred via
membrane spanning receptors into the cytoplasm, reversible tyrosine phosphorylation being the
hallmark of all RTKs. In recent years proteomic approaches have yielded detailed descriptions of
cellular signaling events. Quantitative proteomics is able to characterize the exact position and
strength of post-translational modiﬁcations (PTMs) providing essential information for
understanding the molecular basis of signal transduction. Numerous new post-translational
modiﬁcation sites have been identiﬁed by quantitative mass spectrometry-based proteomics.
In addition, plentiful new players in signal transduction have been identiﬁed underlining the
complexity and the modular architecture of most signaling networks. In this review, we outline
the principles of signal transduction via RTKs and highlight some of the new insights obtained
from proteomic approaches such as protein microarrays and quantitative mass spectrometry.
Introduction
In multicellular organisms cellular survival is dependent on the
proper performance of intercellular communication networks.
Most cellular functions and activities are controlled by extra-
cellular signaling molecules and one generic way to transmit
the signal across the plasma membrane is by transmembrane
receptors. The stimulus is transduced via diﬀerent signaling
cascades to distinct sets of terminal eﬀectors localized
throughout the entire cell, e.g. the cytoskeleton, the nucleus,
and other cellular compartments. One large group of receptors
possesses intrinsic protein tyrosine kinase activity, thus
forming the family of receptor tyrosine kinases (RTKs).1–3
These include epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR) and insulin
receptor (InsR) subfamilies. RTKs are involved in the regulation
of crucial cellular processes such as cell metabolism, growth,
mobility, survival, and most notably cell proliferation and
diﬀerentiation. It is therefore not surprising that deregulated
forms of these receptors (as a result of overexpression or
activating mutations) are involved in the genesis of many
malignancies.1,4
The term proteomics stands for the large scale study of
proteins.5 However, lately the term has been used more
broadly enclosing all kinds of elaborate protein-centric studies.
The analyses of organelles, protein interactions, protein
modiﬁcations, are, amongst others, all part of proteomics.6–9
Proteomics is getting more and more popular due to the higher
sensitivity and throughput of current techniques. The
automation of large scale protein studies allows experimental
set-ups similar to genomic approaches which would not have
been possible a decade ago.10 In the ﬁrst part of this review we
will brieﬂy discuss the principles of signal transduction of
RTKs and in the second part we will highlight the impact of
quantitative proteomics on the current view of RTK signaling.
We will discuss quantitative proteomics approaches focusing
on quantitative mass spectrometry (MS)-based proteomics
and its inﬂuence on the perception of EGFR signaling.
Signal transduction by receptor tyrosine kinases
All RTKs share some common structural and functional
features. They are single polypeptide chains (one exception is
the InsR family where the receptors exist as disulﬁde-linked
dimers), which consist of an extracellular ligand-binding
domain, one transmembrane helix, and a C-terminal cytoplasmic
portion.3,11 The most distinguishing feature of RTKs is the
presence of a tyrosine kinase domain in their intracellular
portion. RTKs also employ similar strategies to trigger
downstream signal transduction.12 Binding of the ligand to
the extracellular parts triggers dimerization and subsequent
autophosphorylation of the receptor subunits, a result of
major signiﬁcance for kinase activation and for downstream
signaling of RTKs.3,13–15 Phosphorylation of conserved
tyrosine residues within the activation loop of the catalytic
domain (e.g., Tyr 1162 for InsR or Tyr 857 for PDGF b
receptors) results in displacement of the activation loop from
the active site and increased enzymatic activity.16–18 The
importance of such an autoregulatory mechanism is supported
by several examples of point mutations in the activation loops
that result in cell transformation due to constitutive kinase
activity.1,4 In contrast to virtually all other RTKs, members of
the EGFR family appear not to employ this autoregulatory
mechanism. Substitution of the conserved tyrosine in the
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activation loop appears not to aﬀect the kinase activity of these
receptors.19 As a result of this loose autoinhibitory function
ErbB2 displays kinase activity even in the absence of ligand
stimulation. Furthermore, as found in numerous malignancies,
the kinase activity of this receptor is strongly enhanced by its
overexpression, causing cell transformation.1,4,20,21
A common theme of the enhanced kinase activity of RTKs
is that it leads to their subsequent autophosphorylation on
tyrosine residues outside the catalytic domain, which are the
key to downstream signaling (Fig. 1). Since the discovery
of protein tyrosine kinases, tyrosine phosphorylation has
been systematically recognized as a major mechanism of
transmembrane signaling, in particular in RTK-mediated
signal transduction. Tyrosine autophosphorylation of RTKs
is critical for the recruitment and activation of a variety of
downstream cytoplasmic targets and subsequent initiation
of dynamic signaling cascades. Indeed, most of the tyrosine
autophosphorylation sites are located outside the catalytic
domain and function as speciﬁc docking sites for Src
homology 2 (SH2) and/or phosphotyrosine binding (PTB)
domains of otherwise structurally and functionally diverse
signaling proteins that are able to propagate the signal in
various ways.3,22–25 The major signaling pathways downstream
of RTKs being the Ras/MAPK (mitogen-activated protein
kinase) signaling cascades, signaling pathways involving
phospholipid second messengers via PLCg (phospholipase
C-g) and PI3K (phosphatidylinositol 30-kinase), and the
STATs (signal transducers and activator of transcription)
pathway (Fig. 1). These have been extensively reviewed over
the years and will not be further described here (for reviews see
ref. 2, 3 and 23).
The speciﬁcity of signal transduction at this initial stage
is directed to a large extent by the amino acid sequence
surrounding the phosphorylated tyrosine residue. This is the
key factor that determines which of the phosphotyrosine-
binding proteins will be recruited to the activated RTK
(from the plethora of SH2/PTB domain-containing proteins
expressed in a given cell). For example, phosphorylation on a
tyrosine residue which is followed by an asparagine residue at
the +2 position results in recruitment of Grb2 (growth factor
receptor-bound protein 2) and subsequent MAPK activation,
whereas the presence of a methionine residue at the +3
position is the key to PI3K binding and the consequent switch
to phospholipid-driven downstream signaling. Some of the
target molecules of RTKs possess intrinsic enzymatic activities,
which are altered by their binding to activated receptors,
resulting in subsequent phosphorylation and/or a conformational
change.26–32 Examples include Src protein tyrosine kinase,
Shp2 protein tyrosine phosphatase, GTPase activating protein
for Ras (Ras GAP), PI3K and PLCg among many others. For
some of these enzymes (e.g., PI3K and PLCg), the recruitment
to RTKs seems to serve a dual function, since it also trans-
locates them to the inner side of the cell membrane where their
substrates are to be found (Fig. 1).33–35 Other signaling
molecules do not contain any catalytic domains and function
as adaptors that bind several proteins at the same time, thus
linking activated receptors to additional proteins involved in
downstream signal propagation.36–38 A prototypical example
is the pivotal adaptor molecule Grb2, which connects a variety
of RTKs to the Ras/MAPK signaling pathway.39,40
Another major aspect of RTK signaling is the proper
attenuation and termination of signal transmission. In order
to maintain their normal cellular functions and physiological
outcomes, the activities of RTKs must be tightly regulated.
Indeed, simultaneous with cell activation, activated receptors
initiate a cascade of events responsible for the subsequent
attenuation and termination of signals. Attenuation and
termination of RTK signaling occurs at various cellular levels
and involves structurally and functionally diverse signaling
molecules. Some of these molecules are protein kinases
downstream of the activated receptors (e.g., PKC and ERK)
that phosphorylate speciﬁc residues, usually serine or threonine
within the juxtamembrane receptor region, and inhibit RTK
activity.41–44 Other important regulators are protein tyrosine
phosphatases (PTPs), which dephosphorylate key tyrosine
residues on activated receptors or downstream signaling
molecules, thereby downregulating RTK-mediated signal
transduction.45,46 A major mechanism responsible for the
attenuation and termination of RTK-mediated signaling,
parallel to the regulatory processes described above, is the
endocytic removal of active receptor–ligand complexes from
the cell surface. Central to these processes appears to be the
covalent conjugation of ubiquitin (monoubiquitination) or a
chain of ubiquitins (polyubiquitination) to the receptor and
downstream signaling molecules (Fig. 1).47–50 Several studies
demonstrated that RTK monoubiquitination on multiple sites
is suﬃcient for both endocytosis and degradation of EGFR
and PDGFR.51,52 However, it was also recently shown that
EGFR can be internalized independently of ubiquitination
events as well.53,54 These studies strongly suggest a robust and
complex internalization process, which can happen dependently
and independently of multiple kinase and ubiquitination
mechanisms.
Due to the importance of RTKs for many aspects of human
biology, RTK signaling has been extensively studied over the
last few decades and a large number of proteins that are
involved in the signaling pathways are already known.
However, most of these proteins do not ﬁt into the canonical
dogma ‘‘one gene-one protein-one function’’ but implement
complex biological functions and are often involved in signaling
networks with distinct or even opposite terminal eﬀects. Also,
in the past few years it became evident that signaling pathways
do not operate as linear cascades, but rather as networks,
allowing cross-talk between diﬀerent pathways involving
various positive and negative feedback signals. In this regard,
large-scale proteomics studies have contributed signiﬁcantly
to the current awareness of the enormous complexity and
dynamics of RTK signaling networks.
Proteomic approaches for elucidation of signaling
pathways
In proteomics, generally large numbers of proteins of given cell
states are analyzed by techniques ranging from protein
microarrays to MS-based approaches. Whereas a few years
ago the mere presence of a protein was analyzed, nowadays
proteomic approaches are quantitatively characterizing changes
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on a proteome-wide scale.55 Recent developments of vigorous
quantitative proteomic strategies allow truly ‘‘functional
proteomics’’ experiments. Temporal changes in protein
composition can now be recorded allowing, for example, cellular
signal transduction to be tracked. Data obtained from temporal
analyses of phosphorylation events reveal insights into cellular
decision making, enabling the construction of time-resolved
signaling networks.56 These network models may allow in silico
predictions of the consequences of network perturbations
happening, e.g. in speciﬁc diseases. Currently, signiﬁcant eﬀorts
are being made into the mathematical modeling of RTK signaling
networks.57 For example, a computational linear mapping
Fig. 1 Major pathways of the EGFR signaling network. A: Signal initiation at the plasma membrane. Ligand binding induces receptor dimerization
followed by transphosphorylation of tyrosine residues. Signaling pathways downstream of EGFR include the Ras/MAP kinase signaling cascade,
signaling pathways involving phospholipid second messengers via PLCg and PI3Ks, signaling via non-receptor tyrosine kinases, and the STAT
pathway. B: Receptor internalization and signal attenuation. EGFR is internalized via caveolae or clathrin-coated pits. Cbl family E3-ligases are
responsible for ubiquitination of receptors. Sorting of receptors for recycling or degradation takes place in early endosomes as well as in
multi-vesicular bodies (MVBs) and it is tightly regulated by diﬀerent endosomal sorting complexes required for transport (ESCRTs) and ubiquitin
binding proteins (for review see ref. 47).
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technique has been used to successfully predict cell migration
and proliferation after ErbB2 stimulation, identifying critical
phosphorylation events.58 Pathway analysis tools for the
characterization of high-throughput ‘‘omics’’ data are
complementing these undertakings.59,60 Ultimately, models
could help the greater understanding of diseases like cancer,
enabling the design of better-directed potent therapies. In
general, targeted and discovery-driven quantitative proteomic
strategies can be distinguished. Targeted analyses such as
protein microarrays, western blot analyses, and phospho-FACS
can be ideally used to analyze single signal nodes in greater
detail over many time points.
The discovery-driven technique par excellence is quantitative
MS-based proteomics, which allows an unbiased global
analysis of cellular protein dynamics and diﬀerential comparison
of entire signaling networks.61,62 MS-based quantitative
proteomic approaches have thereby become the method of
choice for the analysis of PTM-based cellular signaling events.9,63
Thus, global phosphorylation changes can now be studied in
an unbiased approach and a site-speciﬁc characterization and
quantitation of signaling events in vivo is feasible. In the
remaining part of this article we will focus on EGFR signaling
dynamics and discuss the various proteomic strategies, their
ﬁndings and implications on the current view of RTK signaling.
Non-MS-based analyses
A large fraction of the classical non-MS-based analyses rely
on the availability of recombinant proteins and speciﬁc
antibodies. As the sensitivities of antibody-based approaches
are very high, these are optimal if only a limited sample
amount is available, e.g. in a clinical setting. It was however
shown that over 50% of antibodies tested in a whole yeast
proteome screen reacted with multiple targets.64 Nevertheless,
when carefully designed targeted non-MS-based analyses are
of great value in establishing detailed protein interaction
networks. For example, microarrays containing virtually all
human SH2 and PTB domains were used to measure the
dissociation constants for each domain of 61 tyrosine-
phosphorylation sites of the four human ErbB receptors.65
116 new interactions were identiﬁed. Additionally, when
EGFR and ErbB2 were overexpressed, as often occurs in
cancer, they became more promiscuous with lower aﬃnity
thresholds, whereas ErbB3 stayed unchanged. This could
mean that the extent of the protein concentration-dependent
promiscuity change might have an inﬂuence on the oncogenic
potential of a receptor. In a similar approach new interactions
of ErbB4 were described, such as the binding of STAT1.66 It
appeared that ErbB4 interacts more selectively than the other
ErbB receptors. As there is no ligand known for ErbB2, and
ErbB3 is enzymatically inactive, the selectivity of ErbB4 could
enable ErbB2 and ErbB3 to signal independently of EGFR.
In a diﬀerent methodology, laser capture-microdissected
material of human non-small cell lung cancer and a reverse
phase protein array was used to evaluate whether EGFR
mutations inﬂuence phosphorylation levels of EGFR and
downstream components in vivo.67 It was shown that
EGFR mutant carcinomas exhibit increased signaling via the
Akt (PKB)/mTOR pathway, possibly providing survival
advantages compared to cells baring wild type receptors.
Quantitative mass spectrometry
A whole panel of quantitative MS-based proteomic strategies
exist, mostly relying on isotopically labeled peptide counterparts
(Fig. 2).68 It is possible to absolutely quantify signaling events
using techniques such as the AQUA method.69 An isotopically
labeled peptide is synthesized and added in known amounts to
the sample to absolutely quantify its endogenous counterpart.
As this is rather cost intensive, relative quantitation techniques
reporting fold-changes have become widely appreciated. Two
of the best known examples are isobaric tag for relative and
absolute quantitation (iTRAQ) and stable isotope labeling by
amino acids in cell culture (SILAC).70,71 iTRAQ employs
isotope coded covalent tags which are used to chemically label
peptide or protein mixtures. Classically it was used as a
4-plex strategy. However, recently 8-plex iTRAQ has been
introduced.72 Using SILAC, the entire cellular proteome is
metabolically labeled by isotopic variants of amino acids
added to the growth medium. Most commonly, diﬀerent
populations of cells are grown in medium containing three
distinct forms of both arginine (Arg) and lysine (Lys) allowing
3-plex experiments.73 Peptides are labeled by one amino acid
variant when trypsin is used for enzymatic digestion, which
simpliﬁes data analysis as compared to 15N labelling.74,75
Several strategies for label-free protein quantitation have been
suggested, which generally rely on extracted ion currents,
peptide, or spectral counting.10,76–78 Whereas label-free
quantitation has the advantage of reduced costs it is still less
accurate when compared to isotope-labeled analyses.10,79
Thus, to conﬁdently detect e.g. two-fold changes, larger
numbers of experimental replicas are required and signiﬁcantly
more peptides from the corresponding proteins have to be
recorded compared to label-based strategies.80,81
Targeted MS analyses
Targeted MS analyses, e.g. via multiple reaction monitoring
(MRM) or using the AQUA strategy, are not limited by
speciﬁc reagents and yield the highest possible sensitivity for
MS-based type of experiments. Nevertheless, to be included
into these analyses, phosphorylation sites have to be identiﬁed
by discovery-driven approaches, because peptides carrying
regulated phosphorylation sites have distinct physico-chemical
properties, and not all are readily detectable by common mass
analyzers.82 In an initial MRM study a discovery phase was
followed by a subsequent monitoring and quantitation phase.
222 EGF-regulated tyrosine phosphorylation sites (of which
31 were not known) were monitored over seven time points
achieving an experimental reproducibility of 88% compared to
34% in an unbiased approach.83 Additionally, this set-up
increased the dynamic range signiﬁcantly. The high sensitivity
and reproducibility of this technique makes it especially
applicable for the analysis of clinical biopsies, as it will allow
an in-depth monitoring of phosphorylation levels at multiple
signaling nodes.
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Discovery-driven MS analyses
As modiﬁed peptides are present in a substoichiometric
amount, cell fractionation and analyses of subproteomes
enriched in proteins or peptides involved in signal trans-
duction are very useful. For the analysis of phosphopeptides
several enrichment steps are often combined to multi-stage
enrichment strategies, as for example strong cation exchange
chromatography (SCX) and metal-aﬃnity puriﬁcation procedures
such as immobilized metal aﬃnity chromatography (IMAC)
and TiO2 (Fig. 2) (for a recent review see ref. 84).
Fractionation can happen on diﬀerent levels: on the protein
level, which may also allow the identiﬁcation of signal
dependent protein–protein interactions, and on the peptide
level. The enrichment of proteins involved in signaling can
again be achieved by diﬀerent means. In one of the ﬁrst studies
Fig. 2 Experimental design outlines for the analysis of cellular signaling events by quantitative MS. Examples are given for phosphosite-speciﬁc time
course studies of ligand stimulation. A: SILAC approach. SILAC labeled cells are stimulated for various times, lysed, mixed, and ezymatically
digested. Respective peptide mixtures are fractionated by strong cation exchange (SCX) chromatography, phosphopeptides puriﬁed by IMAC or
TiO2, and ﬁnally analyzed by LC-MS/MS (upper panel). Whereas peptides containing not regulated phosphosites show a ratio of 1 : 1 : 1
corresponding to the mixing ratio, peptides bearing positively regulated phosphosites show an increasing ratio. Quantitation is performed in the
MS spectra (middle panel). Ratios can be combined to generate an activation proﬁle (lower panel). B: Four-plex iTRAQ approach. Cells are
stimulated for various times, lysed, ezymatically digested, labeled, and mixed. Respective peptide mixtures are treated like in A (upper panel). In
the MS modes iTRAQ-labeled peptides show one signal, yielding higher intensities and reduced sample composition. Quantitation is done in the
MS/MS modes via the reporter ions 114, 115, 116, and 117 (middle panel). Ratios can be combined to generate an activation proﬁle (lower panel).
C: AQUA approach. Cells are stimulated for various times, lysed, enzymatically digested, and synthetic peptides are spiked into the samples. Each
sample has to be analyzed separately (upper panel). Using spiked peptides allows the absolute quantitation of endogenous counterparts, which is
done in the MS mode (middle panel). Ratios can be combined to generate an activation proﬁle (lower panel).
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to use quantitative MS as a read-out for signal transduction,
proteins associated with activated EGFR were puriﬁed using
the SH2 domain of Grb2 fused to GST as bait.85 SILAC
encoded cells were left untreated or treated with EGF and the
combined lysates were aﬃnity enriched with the recombinant
bait protein. As the SH2 domain binds speciﬁcally to activated
EGFR and Shc, EGF-dependent protein interactions could
readily be analyzed. A total of 228 proteins were identiﬁed of
which 28 were selectively enriched upon stimulation. Next to
well established binding partners such as EGFR, Shc, Vav-2
and Cbl, proteins at that time not known to be involved in
EGFR-dependent signal transduction could be identiﬁed,
e.g. CD59.
Next to domains, peptides can be used to speciﬁcally enrich
proteins involved in signaling events. Using this approach,
interaction partners to all cytosolic tyrosine residues of the
four members of the ErbB-receptor family were determined.86
Pull-down experiments with pairs of phosphorylated and
nonphosphorylated synthetic peptides in combination with
SILAC were performed, indicating that each receptor has
characteristic preferences for interacting proteins and most
interaction partners have multiple binding sites on each
receptor. STAT5 was identiﬁed as a direct binding partner
to EGFR and ErbB4, and new recognition motifs were
discovered for Shc and STAT5.
Protein complexes can also be puriﬁed using antibody-based
strategies, especially regarding phosphotyrosine signaling. As
the relatively large size of the modiﬁed tyrosine residue makes
phosphotyrosines rather immunogenic, very good antibodies
to be used for immunoprecipitation are available. Immuno-
precipitations employing phosphotyrosine antibodies have
been used to delineate EGFR,87–90 InsR,91,92 Her2/neu,93
FGFR,94 and EphB2 receptor signaling.95 On comparison of
PDGF- and EGF-based signaling in mesenchymal stem cell
diﬀerentiation, it was shown that more than 90% of the
signaling proteins were used by both ligands, whereas
the PI3K pathway was exclusively activated by PDGF.90
Chemical inhibition of PI3K in PDGF-stimulated cells
removed the diﬀerential eﬀect of the two growth factors,
implicating it as a control point and highlighting the capability
of quantitative proteomics to directly compare entire signaling
networks and discover critical diﬀerences capable of changing
cell fate. An antibody-based approach was used to characterize
EGFR ubiquitination as well. After stimulation with EGF, six
distinct ubiquitination sites were identiﬁed by tandem MS.
Using an AQUA approach it could be shown that more than
50% of all EGFR-bound ubiquitin derived from polyubiquitin
chains. The majority was Lys63-linked implicating a role of
this linkage in receptor sorting.96 In another study an
antibody-based approach in combination with SILAC was
utilized to study the inﬂuence of protein-tyrosine phosphatase
(PTP) 1B on EGF and PDGF signaling.97 PTP1B-deﬁcient
mouse embryonic ﬁbroblasts were treated and tyrosine
phsophorylation events were compared to wild-type counter-
parts. Eighteen proteins were identiﬁed that harbored
hyperphosphorylated phosphotyrosine sites that could be
functionally linked to PTP1B.
Antibody-based screening for interaction partners in
combination with the analysis of signaling kinetics allows
exciting insights into signal initiation and propagation. By
using SILAC and 5 time points over 20 min of EGF treatment
virtually all known EGFR substrates plus 31 novel eﬀectors
were identiﬁed.88 In addition, the recorded kinetics could be
used to position the proteins in the signal transduction
network. A more recent study utilized a quench-ﬂow system
for the quantitative proteomic assessment of very early cellular
signaling events (qPACE) in combination with SILAC, which
allowed signaling kinetics to be recorded after 0, 1, 5, 10, and
60 s of EGF treatment.89 It could be shown that receptor
autophosphorylation on several tyrosine residues occurs
within seconds of ligand binding. Shc tyrosine phosphorylation
followed almost immediately the phosphorylation of EGFR
indicating that the molecules have to be in close spatial
proximity even without a stimulus being present.98 The
extended range proteomic analysis (ERPA) technique, an
intermediate approach between protein-centric and peptide-
centric proteomics, and label-free quantitation was used to
analyze, in addition to phosphorylation changes, the dynamics
of extracellular glycans on EGFR after stimulation of up to
4 h.77 Although no changes in glycosylation were detected, this
approach might become useful for the comparison of glycan
structures in diﬀerent disease settings.
Antibodies might as well be used for the puriﬁcation
of phosphorylated peptides. Information about non-
phosphorylated interaction partners would be lost, however
the number of identiﬁed phosphorylation sites should increase
due to less non-phosphorylated peptide signals. This approach
was applied in combination with iTRAQ labeling to study
EGFR signaling networks, allowing clustering of activation
proﬁles of single sites.99 Comparing new and known sites in
one cluster provided evidence for the biological role of so far
unknown sites and proteins. This strategy has also been
successfully used for the characterization of Her2/neu and
InsR signaling. Her2/neu signaling was analyzed after EGF
and heregulin (HRG) treatment and it could be shown that
EGF treatment activated multiple signaling pathways
stimulating migration, whereas HRG treatment resulted in
stimulation of a speciﬁc subset of the migratory signaling
network.100 After up to 45 min of insulin treatment 122
tyrosine phosphorylation sites on 89 proteins could be
quantiﬁed. 69 of these sites were not known to respond to
insulin treatment.101 Global surveys of tyrosine-phosphorylated
peptides in cancer cell lines and non-small cell lung cancer
tumors (NSCLC) demonstrated the feasibility of global
screenings using antibody-based approaches, identifying in
one study more than 4500 phosphotyrosine sites on more than
2700 proteins. Known oncogenic kinases such as EGFR and
c-Met as well as RTKs so far not known to be involved in
NSCLC, such as PDGFR, ALK, ROS, and DDR1, were
identiﬁed.102,103
As described above, the characterization of phosphotyrosine-
based signaling events has been performed successfully using
immuno-aﬃnity protocols. However, phosphoserine and
phosphothreonine-based signaling events, which play an
important role in signal propagation and negative feedback
mechanisms of RTKs,3 are more diﬃcult to assess using antibody-
based approaches as these residues are less immunogenic.
Nevertheless, phosphoserine and phosphothreonine-antibodies,
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usually targeting deﬁned phosphorylation motifs of speciﬁc
serine/threonine kinases, have been successfully applied,104
e.g. to study the ATM/ATR signaling pathway.105 To capture
a larger fraction of cellular signaling events happening after
growth factor treatment, global analyses have to be
performed. In a ﬁrst attempt to globally characterize the
EGFR signaling network in an unbiased way, SILAC and
EGF treatment at multiple time points were combined with
SCX fractionation and TiO2 enrichment.
106 Activation
proﬁles of 6600 phosphorylation sites on 2244 proteins were
recorded. More than 1000 sites responded more than 2-fold to
EGF treatment. Among the regulated sites were many known
from EGFR, Shc, and the ERKs. In addition, this study
revealed that there were at least 46 transcriptional regulators
involved in the signaling pathways downstream of EGFR
within the 20 min stimulation period. Numerous novel
phosphorylation sites were identiﬁed including sites from the
transcription factors WBRS9 and DAFT-1. Clustering the
kinetic data revealed functional groups of proteins allowing
the signal cascade to be followed from the plasma membrane
through the cytosol and into the nucleus (Fig. 3). Numerous
cases were detected where sites on the same protein were
regulated diﬀerently, thus highlighting the importance of
analyzing signaling networks both site-speciﬁcally and
quantitatively in order to unveil which of the protein’s
phosphorylation sites are the relevant regulatory switches for
the corresponding functional context or biological system.
Conclusion and future perspectives
Growth factor signaling via RTKs is able to elicit diverse
cellular reactions such as migration and adhesion, diﬀerentiation
and proliferation, survival and apoptosis. The deregulation
of RTK signaling is a hallmark of many cancer types.
Extracellular signals trigger intracellular signaling cascades
based on reversible PTM, phosphorylation being the most
prominent one. Phosphorylation is by far the best studied
cellular PTM which is largely due to the relative ease of
detecting cellular phosphorylation changes. In the last decade,
powerful proteomic approaches have been developed for the
elucidation of cellular signaling cascades which can be based
not only on phosphorylation changes, but on other diverse
PTMs such as glycosylation, acetylation, methylation, and
ubiquitination.107 The new generation of mass spectrometers
have the sensitivity and dynamic range to allow standardized
screenings for modiﬁed peptides and proteins. Thus, MS-based
proteomics in combination with new powerful software tools
promises to holistically uncover the variety and density of
Fig. 3 EGFR signaling network: a view from quantitative phosphoproteomics. Within one minute of EGF treatment tyrosine sites on the receptor
are getting phosphorylated. Direct interactors follow immediately and within ﬁve minutes multiple signaling pathway are fully activated. After ten
minutes, active transcription factors reach the nucleus and set oﬀ gene transcription. Transmitting the signals from the membrane throughout the
entire cell via reversible phosphorylation is a highly dynamic and complex process that involves numerous proteins from various functional
categories and cellular localization. Some of the major categories of regulated phosphoproteins are shown in boxes with corresponding consensus
kinetic curves (modiﬁed from ref. 106).
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PTM combinations on a given protein. Due to MS-based
proteomics the stimulus speciﬁc cross-talk of proteins can be
understood allowing the design of comprehensive network
models which will help to explain cellular decision making.
A major challenge for the future will be to unravel the highly
dynamic nature of signal transduction, to determine the
critical ﬁne-tuning mechanisms that are responsible for speciﬁc
biological outcomes, and to understand how these processes
are aberrant in human diseases. In this regard, quantitative
proteomics has already provided a treasure trove of data.
Numerous novel signaling proteins have been revealed in the
EGFR signaling network alone and thousands of EGF-
dependent kinetics of phosphorylation events have been
recorded as well. The information-rich data generated by
quantitative proteomic approaches allows the formulation of
new hypotheses which have to be tested by experimental
cellular biology approaches to provide a deeper understanding
of their biological signiﬁcance. This is a challenge for the
whole scientiﬁc community and as such is a research endeavor
beyond the operability of a single group or institute.
Acknowledgements
The research leading to these results has received funding from
the European Commission’s 7th Framework Programme
(grant agreement HEALTH-F4-2008-201648/PROSPECTS),
the Danish Medical Research Council, Lunbeck Foundation
and from the Excellence Initiative of the German Federal and
State Governments. IK was supported by the Danish Natural
Science Research Council. JD was supported by the European
Molecular Biology Organization. We thank all CEBI group
members for helpful discussions and support. We apologize to
colleagues whose work was not covered in this review due to
space constrains.
References
1 P. Blume-Jensen and T. Hunter, Oncogenic kinase signalling,
Nature, 2001, 411, 355–365.
2 T. Pawson, Regulation and targets of receptor tyrosine kinases,
Eur. J. Cancer, 2002, 38(Supp. 5), S3–10.
3 J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell,
2000, 103, 211–225.
4 D. S. Salomon, R. Brandt, F. Ciardiello and N. Normanno,
Epidermal growth factor-related peptides and their receptors in
human malignancies, Crit. Rev. Oncol. Hematol., 1995, 19,
183–232.
5 A. Pandey and M. Mann, Proteomics to study genes and
genomes, Nature, 2000, 405, 837–846.
6 T. A. Prokhorova, K. T. Rigbolt, P. T. Johansen, J. Henningsen,
I. Kratchmarova, M. Kassem and B. Blagoev, Stable isotope
labeling by amino acids in cell culture (SILAC) and quantitative
comparison of the membrane proteomes of self-renewing and
diﬀerentiating human embryonic stem cells, Mol. Cell. Proteomics,
2009, 8, 959–970.
7 A. R. Kristensen, S. Schandorﬀ, M. Hoyer-Hansen,
M. O. Nielsen, M. Jaattela, J. Dengjel and J. S. Andersen,
Ordered organelle degradation during starvation-induced autophagy,
Mol. Cell. Proteomics, 2008, 7, 2419–2428.
8 M. Vermeulen, N. C. Hubner and M. Mann, High conﬁdence
determination of speciﬁc protein–protein interactions using
quantitative mass spectrometry, Curr. Opin. Biotechnol., 2008,
19, 331–337.
9 M. Mann and O. N. Jensen, Proteomic analysis of post-
translational modiﬁcations, Nat. Biotechnol., 2003, 21, 255–261.
10 J. Cox and M. Mann, Is proteomics the new genomics?, Cell,
2007, 130, 395–398.
11 P. van der Geer, T. Hunter and R. A. Lindberg, Receptor protein-
tyrosine kinases and their signal transduction pathways,
Annu. Rev. Cell Biol., 1994, 10, 251–337.
12 S. R. Hubbard, M. Mohammadi and J. Schlessinger, Autoregulatory
mechanisms in protein-tyrosine kinases, J. Biol. Chem., 1998, 273,
11987–11990.
13 A. N. Plotnikov, J. Schlessinger, S. R. Hubbard and
M. Mohammadi, Structural basis for FGF receptor dimerization
and activation, Cell, 1999, 98, 641–650.
14 J. Schlessinger, Signal transduction by allosteric receptor
oligomerization, Trends Biochem. Sci., 1988, 13, 443–447.
15 G. Jiang and T. Hunter, Receptor signaling: when dimerization is
not enough, Curr. Biol., 1999, 9, R568–571.
16 W. J. Fantl, D. E. Johnson and L. T. Williams, Signalling by
receptor tyrosine kinases, Annu. Rev. Biochem., 1993, 62,
453–481.
17 L. Naldini, E. Vigna, R. Ferracini, P. Longati, L. Gandino,
M. Prat and P. M. Comoglio, The tyrosine kinase encoded by
the MET proto-oncogene is activated by autophosphorylation,
Mol. Cell. Biol., 1991, 11, 1793–1803.
18 M. F. White, S. E. Shoelson, H. Keutmann and C. R. Kahn,
A cascade of tyrosine autophosphorylation in the beta-subunit
activates the phosphotransferase of the insulin receptor,
J. Biol. Chem., 1988, 263, 2969–2980.
19 N. Gotoh, A. Tojo, M. Hino, Y. Yazaki and M. Shibuya,
A highly conserved tyrosine residue at codon 845 within the
kinase domain is not required for the transforming activity of
human epidermal growth factor receptor, Biochem. Biophys. Res.
Commun., 1992, 186, 768–774.
20 D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich
and W. L. McGuire, Human breast cancer: correlation of relapse
and survival with ampliﬁcation of the HER-2/neu oncogene,
Science, 1987, 235, 177–182.
21 Y. Yarden andM. X. Sliwkowski, Untangling the ErbB signalling
network, Nat. Rev. Mol. Cell Biol., 2001, 2, 127–137.
22 J. Kuriyan and D. Cowburn, Modular peptide recognition
domains in eukaryotic signaling, Annu. Rev. Biophys. Biomol.
Struct., 1997, 26, 259–288.
23 T. Hunter, Signaling—2000 and beyond,Cell, 2000, 100, 113–127.
24 T. Pawson and P. Nash, Protein–protein interactions deﬁne
speciﬁcity in signal transduction, Genes Dev., 2000, 14,
1027–1047.
25 M. B. Yaﬀe, Phosphotyrosine-binding domains in signal
transduction, Nat. Rev. Mol. Cell Biol., 2002, 3, 177–186.
26 S. M. Thomas and J. S. Brugge, Cellular functions regulated by
Src family kinases, Annu. Rev. Cell Dev. Biol., 1997, 13, 513–609.
27 W. Xu, A. Doshi, M. Lei, M. J. Eck and S. C. Harrison,
Crystal structures of c-Src reveal features of its autoinhibitory
mechanism, Mol. Cell, 1999, 3, 629–638.
28 H. K. Kim, J. W. Kim, A. Zilberstein, B. Margolis, J. G. Kim,
J. Schlessinger and S. G. Rhee, PDGF stimulation of inositol
phospholipid hydrolysis requires PLC-gamma 1 phosphorylation
on tyrosine residues 783 and 1254, Cell, 1991, 65, 435–441.
29 P. Hof, S. Pluskey, S. Dhe-Paganon, M. J. Eck and
S. E. Shoelson, Crystal structure of the tyrosine phosphatase
SHP-2, Cell, 1998, 92, 441–450.
30 S. E. Shoelson, M. Sivaraja, K. P. Williams, P. Hu, J. Schlessinger
and M. A. Weiss, Speciﬁc phosphopeptide binding regulates a
conformational change in the PI 3-kinase SH2 domain associated
with enzyme activation, EMBO J., 1993, 12, 795–802.
31 S. Nishibe, M. I. Wahl, S. M. Hernandez-Sotomayor,
N. K. Tonks, S. G. Rhee and G. Carpenter, Increase of the
catalytic activity of phospholipase C-gamma 1 by tyrosine
phosphorylation, Science, 1990, 250, 1253–1256.
32 P. J. Goldschmidt-Clermont, J. W. Kim, L. M. Machesky,
S. G. Rhee and T. D. Pollard, Regulation of phospholipase
C-gamma 1 by proﬁlin and tyrosine phosphorylation, Science,
1991, 251, 1231–1233.
33 L. E. Rameh and L. C. Cantley, The role of phosphoinositide
3-kinase lipid products in cell function, J. Biol. Chem., 1999, 274,
8347–8350.
34 M. P. Czech, PIP2 and PIP3: complex roles at the cell surface,
Cell, 2000, 100, 603–606.
This journal is c The Royal Society of Chemistry 2009 Mol. BioSyst., 2009, 5, 1112–1121 | 1119
35 M. Falasca, S. K. Logan, V. P. Lehto, G. Baccante,
M. A. Lemmon and J. Schlessinger, Activation of phospholipase
C gamma by PI 3-kinase-induced PH domain-mediated
membrane targeting, EMBO J., 1998, 17, 414–422.
36 T. Pawson and P. Nash, Assembly of cell regulatory systems
through protein interaction domains, Science, 2003, 300, 445–452.
37 T. Pawson, M. Raina and P. Nash, Interaction domains: from
simple binding events to complex cellular behavior, FEBS Lett.,
2002, 513, 2–10.
38 T. Pawson and J. D. Scott, Signaling through scaﬀold, anchoring,
and adaptor proteins, Science, 1997, 278, 2075–2080.
39 E. J. Lowenstein, R. J. Daly, A. G. Batzer, W. Li, B. Margolis,
R. Lammers, A. Ullrich, E. Y. Skolnik, D. Bar-Sagi and
J. Schlessinger, The SH2 and SH3 domain-containing protein
GRB2 links receptor tyrosine kinases to ras signaling, Cell, 1992,
70, 431–442.
40 A. M. Tari and G. Lopez-Berestein, GRB2: a pivotal protein in
signal transduction, Semin. Oncol., 2001, 28, 142–147.
41 T. P. Garrington and G. L. Johnson, Organization and regulation
of mitogen-activated protein kinasesignaling pathways,
Curr. Opin. Cell Biol., 1999, 11, 211–218.
42 S. Bowen, K. Stanley, E. Selva and R. J. Davis, Constitutive
phosphorylation of the epidermal growth factor receptor blocks
mitogenic signal transduction, J. Biol. Chem., 1991, 266,
1162–1169.
43 T. Hunter, N. Ling and J. A. Cooper, Protein kinase C phos-
phorylation of the EGF receptor at a threonine residue close to
the cytoplasmic face of the plasma membrane, Nature, 1984, 311,
480–483.
44 B. Su and M. Karin, Mitogen-activated protein kinase cascades
and regulation of gene expression, Curr. Opin. Immunol., 1996, 8,
402–411.
45 M. Elchebly, P. Payette, E. Michaliszyn, W. Cromlish, S. Collins,
A. L. Loy, D. Normandin, A. Cheng, J. Himms-Hagen,
C. C. Chan, C. Ramachandran, M. J. Gresser, M. L. Tremblay
and B. P. Kennedy, Increased insulin sensitivity and obesity
resistance in mice lacking the protein tyrosine phosphatase-1B
gene, Science, 1999, 283, 1544–1548.
46 T. Hunter, Protein kinases and phosphatases: the yin and yang of
protein phosphorylation and signaling, Cell, 1995, 80, 225–236.
47 Y. Mosesson, G. B. Mills and Y. Yarden, Derailed endocytosis:
an emerging feature of cancer, Nat. Rev. Cancer, 2008, 8,
835–850.
48 H. Waterman and Y. Yarden, Molecular mechanisms underlying
endocytosis and sorting of ErbB receptor tyrosine kinases, FEBS
Lett., 2001, 490, 142–152.
49 I. Dikic and S. Giordano, Negative receptor signalling,
Curr. Opin. Cell Biol., 2003, 15, 128–135.
50 D. Hoeller, N. Crosetto, B. Blagoev, C. Raiborg, R. Tikkanen,
S. Wagner, K. Kowanetz, R. Breitling, M. Mann, H. Stenmark
and I. Dikic, Regulation of ubiquitin-binding proteins by
monoubiquitination, Nat. Cell Biol., 2006, 8, 163–169.
51 K. Haglund, S. Sigismund, S. Polo, I. Szymkiewicz, P. P. Di Fiore
and I. Dikic, Multiple monoubiquitination of RTKs is suﬃcient
for their endocytosis and degradation, Nat. Cell Biol., 2003, 5,
461–466.
52 Y. Mosesson, K. Shtiegman, M. Katz, Y. Zwang, G. Vereb,
J. Szollosi and Y. Yarden, Endocytsosis of receptor tyrosine
kinases is driven by mono-, not poly-ubiquitylation, J. Biol. Chem.,
2003, 278, 21323–21326.
53 F. Huang, L. K. Goh and A. Sorkin, EGF receptor ubiquitination
is not necessary for its internalization, Proc. Natl. Acad. Sci.
U. S. A., 2007, 104, 16904–16909.
54 A. Sorkin and L. K. Goh, Endocytosis and intracellular traﬃcking
of ErbBs, Exp. Cell Res., 2008, 314, 3093–3106.
55 J. Cox and M. Mann, MaxQuant enables high peptide
identiﬁcation rates individualized, p.p.b.-range mass accuracies
and proteome-wide protein quantiﬁcation, Nat. Biotechnol., 2008,
26, 1367–1372.
56 A. Gordus, J. A. Krall, E. M. Beyer, A. Kaushansky, A. Wolf-
Yadlin, M. Sevecka, B. H. Chang, J. Rush and G. MacBeath,
Linear combinations of docking aﬃnities explain quantitative
diﬀerences in RTK signaling, Mol. Syst. Biol., 2009, 5, 235.
57 B. N. Kholodenko, Cell-signalling dynamics in time and space,
Nat. Rev. Mol. Cell Biol., 2006, 7, 165–176.
58 N. Kumar, A. Wolf-Yadlin, F. M. White and
D. A. Lauﬀenburger, Modeling HER2 eﬀects on cell behavior
from mass spectrometry phosphotyrosine data, PLoS Comput.
Biol., 2007, 3, e4.
59 R. Linding, L. J. Jensen, G. J. Ostheimer, M. A. van Vugt,
C. Jorgensen, I. M. Miron, F. Diella, K. Colwill, L. Taylor,
K. Elder, P. Metalnikov, V. Nguyen, A. Pasculescu, J. Jin,
J. G. Park, L. D. Samson, J. R. Woodgett, R. B. Russell,
P. Bork, M. B. Yaﬀe and T. Pawson, Systematic discovery
of in vivo phosphorylation networks, Cell, 2007, 129,
1415–1426.
60 R. A. Zubarev, M. L. Nielsen, E. M. Fung, M. M. Savitski,
O. Kel-Margoulis, E. Wingender and A. Kel, Identiﬁcation of
dominant signaling pathways from proteomics expression data,
J. Proteomics, 2008, 71, 89–96.
61 S. J. Ding, W. J. Qian and R. D. Smith, Quantitative proteomic
approaches for studying phosphotyrosine signaling, Expert Rev.
Proteomics, 2007, 4, 13–23.
62 F. M. White, Quantitative phosphoproteomic analysis of signaling
network dynamics, Curr. Opin. Biotechnol., 2008, 19, 404–409.
63 R. Aebersold and M. Mann, Mass spectrometry-based
proteomics, Nature, 2003, 422, 198–207.
64 G. A. Michaud, M. Salcius, F. Zhou, R. Bangham, J. Bonin,
H. Guo, M. Snyder, P. F. Predki and B. I. Schweitzer, Analyzing
antibody speciﬁcity with whole proteome microarrays, Nat.
Biotechnol., 2003, 21, 1509–1512.
65 R. B. Jones, A. Gordus, J. A. Krall and G. MacBeath,
A quantitative protein interaction network for the ErbB receptors
using protein microarrays, Nature, 2006, 439, 168–174.
66 A. Kaushansky, A. Gordus, B. A. Budnik, W. S. Lane, J. Rush
and G. MacBeath, System-wide investigation of ErbB4 reveals 19
sites of Tyr phosphorylation that are unusually selective in their
recruitment properties, Chem. Biol., 2008, 15, 808–817.
67 A. J. VanMeter, A. S. Rodriguez, E. D. Bowman, J. Jen,
C. C. Harris, J. Deng, V. S. Calvert, A. Silvestri, C. Fredolini,
V. Chandhoke, E. F. Petricoin 3rd, L. A. Liotta and V. Espina,
Laser capture microdissection and protein microarray analysis of
human non-small cell lung cancer: diﬀerential epidermal growth
factor receptor (EGPR) phosphorylation events associated with
mutated EGFR compared with wild type, Mol. Cell. Proteomics,
2008, 7, 1902–1924.
68 S. E. Ong and M. Mann, Mass spectrometry-based proteomics
turns quantitative, Nat. Chem. Biol., 2005, 1, 252–262.
69 S. A. Gerber, J. Rush, O. Stemman, M. W. Kirschner and
S. P. Gygi, Absolute quantiﬁcation of proteins and phospho-
proteins from cell lysates by tandem MS, Proc. Natl. Acad. Sci.
U. S. A., 2003, 100, 6940–6945.
70 P. L. Ross, Y. N. Huang, J. N. Marchese, B. Williamson,
K. Parker, S. Hattan, N. Khainovski, S. Pillai, S. Dey,
S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-
Jones, F. He, A. Jacobson and D. J. Pappin, Multiplexed protein
quantitation in Saccharomyces cerevisiae using amine-reactive
isobaric tagging reagents, Mol. Cell. Proteomics, 2004, 3,
1154–1169.
71 S. E. Ong, B. Blagoev, I. Kratchmarova, D. B. Kristensen,
H. Steen, A. Pandey and M. Mann, Stable isotope labeling by
amino acids in cell culture, SILAC, as a simple and accurate
approach to expression proteomics, Mol. Cell. Proteomics, 2002,
1, 376–386.
72 L. Choe, M. D’Ascenzo, N. R. Relkin, D. Pappin, P. Ross,
B. Williamson, S. Guertin, P. Pribil and K. H. Lee, 8-plex
quantitation of changes in cerebrospinal ﬂuid protein expression
in subjects undergoing intravenous immunoglobulin treatment
for Alzheimer’s disease, Proteomics, 2007, 7, 3651–3660.
73 B. Blagoev and M. Mann, Quantitative proteomics to study
mitogen-activated protein kinases, Methods, 2006, 40, 243–250.
74 J. V. Olsen, S. E. Ong and M. Mann, Trypsin cleaves exclusively
C-terminal to arginine and lysine residues,Mol. Cell. Proteomics,
2004, 3, 608–614.
75 Y. Oda, K. Huang, F. R. Cross, D. Cowburn and B. T. Chait,
Accurate quantitation of protein expression and site-speciﬁc
phosphorylation, Proc. Natl. Acad. Sci. U. S. A., 1999, 96,
6591–6596.
76 H. Steen, J. A. Jebanathirajah, M. Springer andM.W. Kirschner,
Stable isotope-free relative and absolute quantitation of protein
1120 | Mol. BioSyst., 2009, 5, 1112–1121 This journal is c The Royal Society of Chemistry 2009
phosphorylation stoichiometry by MS, Proc. Natl. Acad. Sci.
U. S. A., 2005, 102, 3948–3953.
77 S. L. Wu, J. Kim, R. W. Bandle, L. Liotta, E. Petricoin and
B. L. Karger, Dynamic proﬁling of the post-translational
modiﬁcations and interaction partners of epidermal growth factor
receptor signaling after stimulation by epidermal growth factor
using Extended Range Proteomic Analysis (ERPA), Mol. Cell.
Proteomics, 2006, 5, 1610–1627.
78 Y. Ishihama, Y. Oda, T. Tabata, T. Sato, T. Nagasu,
J. Rappsilber and M. Mann, Exponentially modiﬁed protein
abundance index (emPAI) for estimation of absolute protein
amount in proteomics by the number of sequenced peptides per
protein, Mol. Cell. Proteomics, 2005, 4, 1265–1272.
79 M. Bantscheﬀ, M. Schirle, G. Sweetman, J. Rick and B. Kuster,
Quantitative mass spectrometry in proteomics: a critical review,
Anal. Bioanal. Chem., 2007, 389, 1017–1031.
80 W. M. Old, K. Meyer-Arendt, L. Aveline-Wolf, K. G. Pierce,
A. Mendoza, J. R. Sevinsky, K. A. Resing and N. G. Ahn,
Comparison of label-free methods for quantifying human
proteins by shotgun proteomics, Mol. Cell. Proteomics, 2005, 4,
1487–1502.
81 L. N. Mueller, M. Y. Brusniak, D. R. Mani and R. Aebersold, An
assessment of software solutions for the analysis of mass spectro-
metry based quantitative proteomics data, J. Proteome Res.,
2008, 7, 51–61.
82 H. Steen and M. Mann, The ABC’s (and XYZ’s) of peptide
sequencing, Nat. Rev. Mol. Cell Biol., 2004, 5, 699–711.
83 A. Wolf-Yadlin, S. Hautaniemi, D. A. Lauﬀenburger and
F. M. White, Multiple reaction monitoring for robust quantita-
tive proteomic analysis of cellular signaling networks, Proc. Natl.
Acad. Sci. U. S. A., 2007, 104, 5860–5865.
84 B. Macek, M. Mann and J. V. Olsen, Global and site-speciﬁc
quantitative phosphoproteomics: principles and applications,
Annu. Rev. Pharmacol. Toxicol., 2009, 49, 199–221.
85 B. Blagoev, I. Kratchmarova, S. E. Ong, M. Nielsen, L. J. Foster
and M. Mann, A proteomics strategy to elucidate functional
protein–protein interactions applied to EGF signaling,
Nat. Biotechnol., 2003, 21, 315–318.
86 W. X. Schulze, L. Deng and M. Mann, Phosphotyrosine inter-
actome of the ErbB-receptor kinase family,Mol. Syst. Biol., 2005,
1, 0008.
87 A. Pandey, B. Blagoev, I. Kratchmarova, M. Fernandez,
M. Nielsen, T. Z. Kristiansen, O. Ohara, A. V. Podtelejnikov,
S. Roche, H. F. Lodish and M. Mann, Cloning of a novel
phosphotyrosine binding domain containing molecule, Odin,
involved in signaling by receptor tyrosine kinases, Oncogene,
2002, 21, 8029–8036.
88 B. Blagoev, S. E. Ong, I. Kratchmarova and M. Mann, Temporal
analysis of phosphotyrosine-dependent signaling networks by
quantitative proteomics, Nat. Biotechnol., 2004, 22, 1139–1145.
89 J. Dengjel, V. Akimov, J. V. Olsen, J. Bunkenborg, M. Mann,
B. Blagoev and J. S. Andersenm, Quantitative proteomic assess-
ment of very early cellular signaling events, Nat. Biotechnol.,
2007, 25, 566–568.
90 I. Kratchmarova, B. Blagoev, M. Haack-Sorensen, M. Kassem
and M. Mann, Mechanism of divergent growth factor eﬀects in
mesenchymal stem cell diﬀerentiation, Science, 2005, 308,
1472–1477.
91 N. Ibarrola, H. Molina, A. Iwahori and A. Pandey, A novel
proteomic approach for speciﬁc identiﬁcation of tyrosine kinase
substrates using [13C]tyrosine, J. Biol. Chem., 2004, 279,
15805–15813.
92 M. Kruger, I. Kratchmarova, B. Blagoev, Y. H. Tseng,
C. R. Kahn and M. Mann, Dissection of the insulin signaling
pathway via quantitative phosphoproteomics, Proc. Natl. Acad.
Sci. U. S. A., 2008, 105, 2451–2456.
93 R. Bose, H. Molina, A. S. Patterson, J. K. Bitok, B. Periaswamy,
J. S. Bader, A. Pandey and P. A. Cole, Phosphoproteomic
analysis of Her2/neu signaling and inhibition, Proc. Natl. Acad.
Sci. U. S. A., 2006, 103, 9773–9778.
94 A. M. Hinsby, J. V. Olsen and M. Mann, Tyrosine phospho-
proteomics of ﬁbroblast growth factor signaling: a role for
insulin receptor substrate-4, J. Biol. Chem., 2004, 279,
46438–46447.
95 G. Zhang, D. S. Spellman, E. Y. Skolnik and T. A. Neubert,
Quantitative phosphotyrosine proteomics of EphB2 signaling by
stable isotope labeling with amino acids in cell culture (SILAC),
J. Proteome Res., 2006, 5, 581–588.
96 F. Huang, D. Kirkpatrick, X. Jiang, S. Gygi and A. Sorkin,
Diﬀerential regulation of EGF receptor internalization and
degradation by multiubiquitination within the kinase domain,
Mol. Cell, 2006, 21, 737–748.
97 P. Mertins, H. C. Eberl, J. Renkawitz, J. V. Olsen,
M. L. Tremblay, M. Mann, A. Ullrich and H. Daub, Investiga-
tion of protein-tyrosine phosphatase 1B function by quantitative
proteomics, Mol. Cell. Proteomics, 2008, 7, 1763–1777.
98 J. Dengjel, V. Akimov, B. Blagoev and J. S. Andersen, Signal
transduction by growth factor receptors: signaling in an instant,
Cell Cycle, 2007, 6, 2913–2916.
99 Y. Zhang, A. Wolf-Yadlin, P. L. Ross, D. J. Pappin, J. Rush,
D. A. Lauﬀenburger and F. M. White, Time-resolved mass
spectrometry of tyrosine phosphorylation sites in the epidermal
growth factor receptor signaling network reveals dynamic
modules, Mol. Cell. Proteomics, 2005, 4, 1240–1250.
100 A. Wolf-Yadlin, N. Kumar, Y. Zhang, S. Hautaniemi,
M. Zaman, H. D. Kim, V. Grantcharova, D. A. Lauﬀenburger
and F. M. White, Eﬀects of HER2 overexpression on cell signaling
networks governing proliferation and migration,Mol. Syst. Biol.,
2006, 2, 54.
101 K. Schmelzle, S. Kane, S. Gridley, G. E. Lienhard and
F. M. White, Temporal dynamics of tyrosine phosphorylation
in insulin signaling, Diabetes, 2006, 55, 2171–2179.
102 K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack,
J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes,
L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren,
J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser,
B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu,
R. D. Polakiewicz, J. Rush and M. J. Comb, Global survey of
phosphotyrosine signaling identiﬁes oncogenic kinases in lung
cancer, Cell, 2007, 131, 1190–1203.
103 J. Rush, A. Moritz, K. A. Lee, A. Guo, V. L. Goss, E. J. Spek,
H. Zhang, X. M. Zha, R. D. Polakiewicz and M. J. Comb,
Immunoaﬃnity proﬁling of tyrosine phosphorylation in cancer
cells, Nat. Biotechnol., 2005, 23, 94–101.
104 M. Gronborg, T. Z. Kristiansen, A. Stensballe, J. S. Andersen,
O. Ohara, M. Mann, O. N. Jensen and A. Pandey, A mass
spectrometry-based proteomic approach for identiﬁcation of
serine/threonine-phosphorylated proteins by enrichment with
phospho-speciﬁc antibodies: identiﬁcation of a novel protein,
Frigg, as a protein kinase A substrate, Mol. Cell. Proteomics,
2002, 1, 517–527.
105 M. P. Stokes, J. Rush, J. Macneill, J. M. Ren, K. Sprott,
J. Nardone, V. Yang, S. A. Beausoleil, S. P. Gygi,
M. Livingstone, H. Zhang, R. D. Polakiewicz and M. J. Comb,
Proﬁling of UV-induced ATM/ATR signaling pathways,
Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 19855–19860.
106 J. V. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar,
P. Mortensen and M. Mann, Global, in vivo, and site-speciﬁc
phosphorylation dynamics in signaling networks, Cell, 2006, 127,
635–648.
107 T. Hunter, The age of crosstalk: phosphorylation, ubiquitination,
and beyond, Mol. Cell, 2007, 28, 730–738.
This journal is c The Royal Society of Chemistry 2009 Mol. BioSyst., 2009, 5, 1112–1121 | 1121
